Epicardial coronary artery tone and reactivity in patients with normal coronary arteriograms and reduced coronary flow reserve (syndrome X)  by Kaski, Juan Carlos et al.
50 JACC Vol. 18, No. I 
July 1991:50-4 
Epicardial Coronary Artery Tone and Reactivity in Patients With 
Normal Coronary Arteriograms and Reduced Coronary Flow 
Reserve (Syndrome X) 
JUAN CARLOS KASKI, MD, FACC, DIMITRIS TOUSOULIS, MD, ALFREDO R. GALASSI, MD, 
EUGENE McFADDEN, MRCP, WAGNER I. PEREIRA, MD, FILIPPO CREA, MD, FACC, 
ATTILIO MASERI, FRCP, FACC 
London, England 
The vasomotor response of proximal and distal angiographically 
normal coronary artery segments was studied in 12 patients with 
syndrome X, 17 age- and gender-matched patients with chronic 
stable angina and 10 control subjects with atypical chest pain and 
a normal coronary arteriogram. Ergonovine (300 p.g by intrave-
nous injection) and isosorbide dinitrate (1 mg by intracoronary 
injection) were administered to all patients. Computerized coro-
nary artery diameter measurement (angiographically normal seg-
ments only) was carried out before and after the administration of 
ergonovine and nitrate. 
Baseline intraluminal diameters (mean ± SEM) of proximal 
and distal coronary segments were not significantly different in 
control subjects and patients with syndrome X or coronary artery 
disease (proximal 2.88 ± 0.19, 3.01 ± 0.13 and 2.86 ± 0.13 mmj 
distal 1.57 ± 0.09, 1.70 ± 0.10 and 1.61 ± 0.06 mm, respectively). 
With ergonovine, proximal segments constricted by 10 ± 2%, 7 ± 
2% and 11 ± 3% and distal segments by 12 ± 3%,14 ± 3% and 
14 ± 2% in control subjects and patients with syndrome X or 
Patients with microvascular angina (1) or syndrome X (2-4) 
have typical exertional angina that appears to be caused by 
an abnormal vasodilator capacity of the coronary microcir-
culation (1,3,5-7). In these patients, ergonovine can exacer-
bate limited coronary flow reserve during pacing in the 
absence of focal epicardial coronary artery spasm (7). Be-
cause a large proportion of patients with syndrome X have 
angina at rest and ischemia-like ST segment depression 
during ambulatory electrocardiographic (ECG) monitoring, 
which is not always preceded by an increase in heart 
rate, dynamic small vessel constriction has also been sug-
gested (4) to playa role in the genesis of angina in these 
patients. 
Recently, it was suggested (8) that patients with micro-
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coronary artery disease, respectively (p = NS). With isosorbide 
dinitrate, proximal coronary segments dilated by 11 ± 2%, 10 ± 
2% and 8 ± 2% (p = NS) and distal segments by 15 ± 2%, 11 ± 
3% and 13 ± 2% (p = NS) in control subjects and patients with 
syndrome X or coronary artery disease, respectively. Within 
groups, constriction in response to ergonovine and dilation in 
response to nitrate were not significantly different in proximal and 
distal segments. 
The results of this study indicate that coronary diameters and 
the vasomotor response to ergonovine and isosorbide dinitrate of 
angiographically normal coronary artery segments at rest are not 
significantly different in patients with noncardiac chest pain, 
syndrome X or coronary artery disease. Although coronary flow 
reserve is impaired in patients with syndrome X, reactivity of 
large epicardial vessels to nitrate and ergonovine is within the 
physiologic range in these patients. 
(J Am Coli CardioI1991;18:50-4) 
vascular angina have an abnormal vasodilator reactivity that 
affects not only their coronary vascular smooth muscle, but 
also the systemic vasculature. Moreover, although most 
evidence indicates that the primary alteration responsible for 
microvascular angina or syndrome X lies in the coronary 
microcirculation, recent reports (9-11) suggest an alteration 
of the reactivity of epicardial coronary arteries in these 
patients. A diffuse abnormal epicardial coronary constrictor 
response to hyperventilation (9) and an "erratic" epicardial 
vasodilator response to nifedipine (10) have been reported in 
patients with syndrome X. It has also been shown (11) that in 
patients with normal coronary arteries and reduced coronary 
flow reserve, distal epicardial coronary arteries exhibit ab-
normal vasomotion during exercise. 
We prospectively compared, using quantitative coronary 
arteriography, coronary artery diameters and reactivity of 
epicardial coronary arteries at rest in response to ergonovine 
and isosorbide 4initrate in patients with syndrome X, pa-
tients with chronic stable angina and individuals with atyp-
ical chest pain and a normal coronary arteriogram. 
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Methods 
Study patients. The study group comprised 39 patients; 
10 had atypical chest pain and a normal coronary arterio-
gram (control group), 12 had syndrome X and 17 had chronic 
stable angina due to atheromatous coronary artery disease. 
Control group. Five women and five men, aged 35 to 61 
years (mean 49), were studied. These patients had atypical 
chest pain, a normal exercise test and angiographically 
normal coronary arteries. All had been referred for coronary 
arteriography by their treating physician. None of these 
patients had left ventricular hypertrophy, which was as-
sessed by two-dimensional guided M-mode echocardio-
grams. Measurements were obtained according to American 
Society of Echocardiography recommendations (12). Left 
ventricular wall thickness was calculated as the arithmetic 
mean of both posterior and interventricular septal thickness, 
and left ventricular mass was calculated with the method 
proposed by Troy et al. (13). Left ventricular hypertrophy 
was excluded by using gender-specific normal limits from the 
Framingham study (14). Systemic hypertension (defined as a 
blood pressure> 140/90 mm Hg in repeated readings), coro-
nary artery spasm, cardiomyopathy, valvular heart disease 
or conduction disturbances were not present in any patient. 
In these individuals, chest pain was most probably of non-
cardiac origin. Coronary blood flow reserve in response to 
dipyridamole was assessed in 5 of the 10 patients, by 
positron emission tomography using oxygen-15-labeled wa-
ter (15) and was found to be 2::3.5 in all (range 3.5 to 4.6), a 
finding consistent with normal values from our laboratory 
(3.95 ± 0.9 in normal volunteers) (16) and results obtained by 
other investigators (17) using a similar technique. 
Syndrome X. Syndrome X was defined as typical exer-
tional angina, a positive exercise test (2::2 mm of ST segment 
depression), abnormal coronary blood flow reserve and a 
completely normal coronary arteriogram. Eight women and 
four men, aged 36 to 67 years (mean 52), were included in the 
study. None of the patients had left ventricular hypertrophy, 
which was assessed as in the control group (left ventricular 
mass index ranged from 78 to 95 g!m2 in the eight women and 
from 83 to 122 g!m2 in the four men). Patients with conduc-
tion disturbances, systemic hypertension, coronary artery 
spasm, cardiomyopathy or valvular heart disease were not 
included. All patients with syndrome X included in the study 
had episodes of horizontal or downsloping ST segment 
depression during 24 h ambulatory ECG monitoring and 
eight had reversible regional perfusion abnormalities during 
exercise, as assessed by hexamibi technetium-99m scans in 
six and by positron emission tomography (rubidium-82) in 
the remaining two. Coronary blood flow reserve in response 
to intravenous dipyridamole, assessed by positron emission 
tomography, was reduced in all 12 patients (mean 2.2 ± 0.4), 
a finding also reported by Geltman et al. (17) using a similar 
technique. 
Coronary artery disease. Seventeen patients (7 men and 
10 women), aged 36 to 70 years (mean 51), with chronic 
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stable exertional angina, an abnormal exercise test and 
angiographically documented single vessel coronary artery 
disease (2::50% fixed reduction in intraluminal diameter) 
were studied. They were age- and gender-matched with 
control patients and patients with syndrome X. No patient 
had left ventricular hypertrophy or a history of myocardial 
infarction and all had a normal baseline ECG and left 
ventricular function at rest. 
Study Protocol 
The study protocol was approved by the hospital's Ethics 
Committee. The nature of the study was explained to each 
subject before written informed consent was obtained. 
Coronary arteriography. All antianginal medication was 
discontinued 2::48 h before the study, with the exception of 
sublingual nitrates, which were allowed for relief of anginal 
attacks. All patients were fasting and had not smoked or 
received nitrates for acute pain for 2::8 h before cardiac 
catheterization. After diagnostic coronary arteriography, 
orthogonal views of relevant coronary artery segments were 
obtained before the administration of ergonovine or nitrate 
(baseline control arteriograms). Only angiographically nor-
mal segments were considered for analysis. Ergonovine 
(300 p,g) was administered intravenously to all patients and 
arteriograms were repeated 2 to 4 min after administration. 
In all patients, a second control coronary arteriogram was 
obtained 5 to 7 min after ergonovine administration, before 
the intracoronary injection of isosorbide dinitrate (1 mg). 
Arteriograms of the relevant coronary segments were re-
peated 2 to 4 min after administration of the nitrate. 
Measurement of coronary artery diameters. Our tech-
nique to measure coronary artery diameters was reported in 
detail previously (18). Briefly, coronary lumen diameters 
were measured by an automated edge contour detection 
system (Coronary Angiography Analysis System [CAAS], 
Pie Data Medical). The stem of the Judkins coronary cath-
eter was used for calibration to determine absolute measure-
ments in millimeters, and correction was made for radio-
graphic pincushion distortion. Arteriograms were analyzed 
by two independent observers and later reanalyzed without 
knowledge of previous findings to determine the reproduc-
ibility of the method. The repeatability of the measurements 
was quantified by calculating the difference of each vessel 
measurement from the average of the measurement of that 
vessel (intraobserver reproducibility of measurements = 
98%). There were no statistically (analysis of variance) 
significant differences between observers (F = 0.31, p = 
0.70). 
All major coronary arteries were divided in thirds using 
the American Heart Association classification (19). For the 
purpose of the study, only angiographically normal segments 
located in proximal and distal locations were analyzed. 
Diseased segments in patients with coronary artery disease 
were excluded from analysis because in the three patient 
groups we tried to compare only the vasomotor response of 
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Table 1. Coronary Diameter on Baseline Arteriograms and Arteriograms Mter Intravenous Ergonovine in 39 Patients 
Proximal Coronary Segments 
Baseline Ergonovine 
(mm) (mm) 
Control patients (n = 10) 2.88 ± 0.19 2.62 ± 0.2 
Syndrome X (n = 12) 3.01 ± 0.13 2.80 ± 0.14 
CAD (n = 17) 2.86 ± 0.13 2.54 ± 0.15 
CAD = coronary artery disease. 
coronary arteries that looked angiographically normal. In 
three patients who had multiple lesions in the diseased 
vessel, this artery was excluded from analysis altogether. 
The percent vasoconstriction in response to ergonovine and 
dilation in response to nitrate used to quantify changes in 
coronary artery diameter were calculated as follows: 
Constriction by ergonovine = {(Control diameter -
Diameter after ergonovine)/ Control diameter} x 100%. 
Dilation by nitrate = {(Diameter after nitrate -
Control diameter)/ Control diameter} x 100 (%). 
Data analysis. Coronary diameter data are presented as 
mean values ± SEM, and hemodynamic variables as mean 
values ± 1 SD. Differences between proportions were ana-
lyzed by the Yates corrected chi-square test. Paired and 
unpaired Student's t tests were used as appropriate to 
analyze continuous data. A p value < 0.05 was considered 
significant. 
Results 
Baseline and control coronary artery diameters. We ana-
lyzed 36 angiographically normal segments in 10 subjects in 
the control group, 34 segments in the 12 patients with 
syndrome X and 29 segments in the 17 patients with coro-
nary artery disease. Mean baseline diameter of proximal and 
distal coronary segments was similar in patients with atypi-
cal chest pain (control group), syndrome X or coronary 
artery disease (proximal 2.88 ± 0.19, 3.01 ± 0.13 and 2.86 ± 
0.13 mm, respectively; distal 1.57 ± 0.09, 1.70 ± 0.10 and 
1.61 ± 0.06 mm, respectively) (Table 1, Fig. 1). Baseline 
coronary diameter of proximal and distal segments before 
ergonovine and baseline control diameter before isosorbide 
dinitrate were not significantly different in control subjects 
and patients with syndrome X or coronary artery disease 
(Tables 1 and 2). 
Effects of ergonovine on coronary artery diameter (Table 
1). The intravenous administration of ergonovine consis-
tently caused a mild increase in systolic blood pressure, but 
heart rate did not change. The hemodynamic response to 
ergonovine was similar in the three patient groups. Com-
pared with baseline values, systolic blood pressure increased 
by 7 ± 4, 9 ± 5 and 9 ± 4 mm Hg, respectively, whereas 
Distal Coronary Segments 
% Baseline Ergonovine % 
Reduction (mm) (mm) Reduction 
-10 ± 2 1.57 ± 0.09 1.38 ± 0.08 -12 ± 3 
-7 ± 2 1.70 ± 0.10 1.46 ± 0.13 -14 ± 3 
-11 ± 3 1.61 ± 0.06 1.39 ± 0.07 -14 ± 2 
heart rate changed by 2 ± 3, 1 ± 4 and 3 ± 2 beats/min in 
control subjects and patients with syndrome X or coronary 
artery disease, respectively. 
After the administration of ergonovine, all patients with 
coronary artery disease had mild diffuse coronary constric-
tion. Segments with marked diameter reduction by athero-
matous plaques constricted to an extent similar to that of 
angiographically normal segments, but coronary occlusion 
did not occur in any case. 
Proximal coronary segments reduced their caliber by 10 
± 2%, 7 ± 2% and 11 ± 3% in the control subjects and 
patients with syndrome X or coronary artery disease, re-
spectively (p = NS). Distal coronary segments in these three 
patient groups reduced their mean caliber by 12 ± 3%, 14 ± 
3% and 14 ± 2%, respectively (p = NS) (Fig. 2 and 3). 
Within groups, diameter reduction in response to er-
gonovine was not significantly different in proximal and 
distal segments (Table 1). However, in patients with syn-
drome X, distal coronary segments showed greater constric-
tion than proximal segments (p = 0.09). 
Response to intracoronary isosorbide dinitrate (Table 2). 
Vasodilation of proximal coronary segments after nitrate 
was 11 ± 2% in the control group, 10 ± 2% in those with 
syndrome X and 8 ± 2% in patients with coronary artery 
disease (p = NS) (Fig. 2 and 3). Dilation of distal segments 
after nitrate in these three groups was 15 ± 2%, 11 ± 3% and 
13 ± 2%, respectively (p = NS) (Fig. 2 and 3). 
Within groups, dilation of proximal and distal coronary 
segments was not significantly different. However, in pa-
Figure 1. Mean baseline coronary artery diameter of angiographi-
cally normal proximal and distal coronary artery segments in control 
subjects and patients with syndrome X or coronary artery disease 
(CAD). Basal coronary diameters were similar in the three groups. 
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Table 2. Coronary Diameter on Baseline Arteriograms and Arteriograms After Intravenous Isosorbide Dinitrate in 39 Patients 
Proximal Coronary Segments 
Baseline ISDN 
(mm) (mm) 
Control patients (n = 10) 3.02 ± 0.14 3.40 ± 0.15 
Syndrome X (n = 12) 2.8 ± 0.08 3.06 ± 0.07 
CAD (n = 17) 2.84 ± 0.12 3.09 ± 0.12 
CAD = coronary artery disease; ISDN = isosorbide dinitrate. 
tients with coronary artery disease, coronary dilation in 
response to isosorbide dinitrate was greater in distal than in 
proximal segments (p == 0.07). 
Discussion 
This study demonstrates that mean basal coronary diam-
eter is not significantly different in patients with atypical 
chest pain, syndrome X or coronary artery disease and that 
the response of proximal and distal angiographically normal 
coronary artery segments to nonendothelial-dependent 
vasoactive substances is similar in these three groups of 
patients. 
Coronary response to ergonovine. Our findings with er-
gonovine are in agreement with observations of Cannon et 
al. (7) in patients with microvascular angina. These investi-
gators found that the limitation in flow reserve caused by 
ergonovine, which resulted in myocardial ischemia, was not 
due to focal epicardial coronary spasm, because only mild 
diffuse epicardial constriction developed with ergonovine in 
their patients. In our study, the hemodynamic response to 
ergonovine was similar in the three patient groups and 
consistent with findings by others (20,21). In our patients 
with syndrome X, coronary constriction caused by er-
gonovine was within the physiologic range and similar to that 
in control patients and patients with chronic stable angina 
(20,21). 
Our results do not confirm the findings by Bugiardini et al. 
Figure 2. Coronary artery vasodilation after intracoronary isosor-
bide dinitrate (left) and constriction after intravenous ergonovine 
(right) of angiographically normal proximal segments. No significant 
differences in the response to nitrate and ergonovine were observed 
in the control subjects and patients with syndrome X or coronary 
artery disease (CAD). 
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Distal Coronary Segments 
% Baseline ISDN % 
Dilation (mm) (mm) Dilation 
\I ± 2 1.59 ± 0.06 1.80 ± 0.07 15 ± 2 
10 ± 2 1.65 ± 0.07 1.82 ± 0.07 II ± 3 
8 ± 2 1.56 ± 0.05 1.76 ± 0.06 \3 ± 2 
(9) of marked diffuse generalized epicardial coronary con-
striction in response to vasoconstrictor stimuli in patients 
with syndrome X. We found that in our patients with angina, 
a normal coronary arteriogram and reduced coronary flow 
reserve, epicardial coronary reactivity to constrictor stimuli 
was within the physiologic range. Because the observations 
of Bugiardini et al. (9) were preliminary and a complete 
clinical description of their patients is lacking, it is possible 
that differences in patient selection may explain the different 
findings. In addition, the constrictor agents used differed in 
the two studies and quantitative computerized angiographic 
analysis was not carried out (9). 
The distal coronary segments in our patients with syn-
drome X had greater (although the difference was not 
statistically significant) reactivity in response to ergonovine 
than did the proximal segments. This finding might be in 
agreement with the observation by Bortone et al. (11) that 
distal epicardial vessels constrict during exercise in patients 
with angina and normal coronary arteries, suggesting an 
abnormal behavior of these vessels in syndrome X. In our 
study, however, the mean diameter of small distal epicardial 
coronary vessels during baseline study and after nitrate 
administration was not significantly different in those with 
syndrome X, control subjects and patients with coronary 
artery disease. It is conceivable that the altered vasomotor 
response found by Bortone et al. (1\) could be due to a 
diminished flow-dependent release of endothelium-derived 
relaxing factor, as also suggested by others (22). 
Figure 3. Coronary artery vasodilation after intracoronary isosor-
bide dinitrate (left) and constriction after intravenous ergonovine 
(right) of angiographically normal distal segments. Reactivity of 
distal epicardial coronary segments was not significantly different in 
control subjects and patients with syndrome X or coronary artery 
disease (CAD). 
20 -~ 0 - 10 Q) 
en c: 
ftI .c: 0 u .... 
Q) -Q) -10 Control E 
ftI Syndrome X 
Q 
-20 
CAD 
54 KASKI ET AL. 
EPICARDIAL CORONARY REACTIVITY IN SYNDROME X 
Coronary response to isosorbide dinitrate. In our study, 
epicardial coronary dilation with isosorbide dinitrate in 
patients with syndrome X was similar to that observed in the 
control group and in patients with coronary artery disease. 
Observations reported by Montorsi et al. (10) that the 
vasodilator response of coronary arteries to sublingual nife-
dipine is rather erratic in syndrome X were not confirmed in 
our study. Proximal and distal vessels consistently dilated in 
response to nitrate in all our patients with syndrome X. 
These differences could be explained by the greater potential 
of isosorbide dinitrate for dilation of epicardial coronary 
arteries in comparison with sublingual nifedipine (23). More-
over, because syndrome X is an ill defined patient category 
that in its broadest definition probably encompasses patients 
with different causes of their anginal pain, differences in 
patient selection could also explain the different findings. In 
addition to angina and an abnormal exercise test, our pa-
tients had reduced coronary flow reserve, whereas the 
Italian patients (10) were selected mainly on the basis of 
angina and an abnormal exercise test and it is not known 
whether they had an abnormal coronary flow reserve. In 
keeping with our findings, however, the response to nife-
dipine in the patients with syndrome X studied by Montorsi 
et al. (10) was, on average, similar to that of normal coronary 
branches in patients with classic effort angina previously 
reported by De Cesare et al. (24) from the same institution. 
Conclusions. The results of our study indicate that de-
spite the presence of an abnormal vasodilator capacity of the 
coronary microcirculation, epicardial coronary reactivity to 
nonendothelial-dependent vasoactive substances is normal 
in patients with syndrome X. Further studies to assess 
endothelial function in patients with this syndrome are 
necessary. 
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